{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.1","upperLimit":"15.0","value":"9.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Progression-Free Survival is the period from study entry until disease progression, death or date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bevacizumab 15 mg/kg IV every 21 days until disease progression or adverse effects prohibit further treatment","id":"OG000","title":"Bevacizumab"}],"paramType":"MEDIAN","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","timeFrame":"Every other cycle for 6 months; then every 3 months for two years; then every six months for three years; and at any other time if clinically indicated based on symptoms, physical signs suggestive of progressive disease or rising serum tumor maker levels","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}